Ascletis Pharma Inc.
ASCLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | -0.07 | -0.32 | -0.00 |
| FCF Yield | -2.69% | -8.14% | -19.64% | -6.36% |
| EV / EBITDA | -26.42 | -3.85 | -4.23 | -4.26 |
| Quality | ||||
| ROIC | -10.13% | -14.94% | -7.92% | -9.65% |
| Gross Margin | 11.19% | 57.29% | 0.00% | -125.17% |
| Cash Conversion Ratio | 1.97 | 0.81 | 1.56 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -58.12% | -34.76% | -34.38% | -31.19% |
| Free Cash Flow Growth | -23.34% | 31.05% | -152.48% | -15.41% |
| Safety | ||||
| Net Debt / EBITDA | 8.58 | 3.82 | 2.01 | 1.45 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | 0.13 | 0.00 | 3.74 |
| Cash Conversion Cycle | 484.16 | 1,073.80 | 0.00 | 69.93 |